Amphastar Pharmaceuticals Reports 75% Drop in Q1 GAAP Net Income

summarizeSummary

Amphastar Pharmaceuticals, Inc. announced its first-quarter 2026 financial results, reporting a significant 75% year-over-year decline in GAAP net income and a substantial drop in diluted EPS, despite flat net revenues.

check_boxKey Events

• GAAP Net Income Plummets

  Reported GAAP net income of $6.4 million for Q1 2026, a 75% decrease from $25.3 million in Q1 2025.

• Diluted EPS Declines Sharply

  GAAP diluted EPS fell to $0.14 for Q1 2026, down from $0.51 in the prior year's quarter.

• Gross Margin Compression

  Gross profit decreased by 18% to $70.3 million, with gross margin falling from 50.0% to 41.1% of net revenues.

• Flat Net Revenues

  Net revenues remained largely flat at $171.2 million compared to $170.5 million in Q1 2025.

auto_awesomeAnalysis

Amphastar Pharmaceuticals, Inc. announced its first-quarter 2026 financial results, reporting a significant 75% year-over-year decline in GAAP net income and a substantial drop in diluted EPS, despite flat net revenues. This significant decline was primarily driven by lower gross margins on key products like BAQSIMI® and glucagon, coupled with increased manufacturing, legal, and R&D expenses, including a $2.0 million upfront payment for a new licensing agreement. While net revenues remained flat, the substantial reduction in profitability and gross margin compression indicate significant operational challenges and competitive pressures, which could impact investor sentiment and future earnings expectations.